본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

Genes, chromosomes & cancer v.56 no.4, 2017년, pp.255 - 265   SCI SCIE SCOPUS
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Targeted next‐generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance

Pfarr, Nicole (Institute of Pathology University Hospital Heidelberg, Heidelberg, Germany ) ; Penzel, Roland (Institute of Pathology University Hospital Heidelberg, Heidelberg, Germany ) ; Endris, Volker (Institute of Pathology University Hospital Heidelberg, Heidelberg, Germany ) ; Lier, Clemens (Institute of Pathology University Hospital Heidelberg, Heidelberg, Germany ) ; Flechtenmacher, Christa (Institute of Pathology University Hospital Heidelberg, Heidelberg, Germany ) ; Volckmar, Anna‐Lena (Institute of Pathology University Hospital Heidelberg, Heidelberg, Germany ) ; Kirchner, Martina (Institute of Pathology University Hospital Heidelberg, Heidelberg, Germany ) ; Budczies, Jan (Institute of Pathology Charité ) ; Leichsenring, Jonas (University Hospital, Berlin, Germany ) ; Herpel, Esther (Institute of Pathology University Hospital Heidelberg, Heidelberg, Germany<count ) ; Noske, Aurelia ; Weichert, Wilko ; Schneeweiss, Andreas ; Schirmacher, Peter ; Sinn, Hans‐Peter ; Stenzinger, Albrecht ;
  • 초록  

    HER2‐positive breast cancers are a heterogeneous group of tumors, which share amplification and overexpression of HER2. In routine diagnostics, the HER2 ( ERBB2 ) status is currently assessed by immunohistochemistry (IHC) and in situ hybridization (ISH). Data on targeted next‐generation sequencing (NGS) approaches that could be used to determine the HER2 status are sparse. Employing two breast cancer‐related gene panels, we performed targeted NGS of 41 FFPE breast cancers for which full pathological work‐up including ISH and IHC results was available. Selected cases were analyzed by qPCR. Of the 41 cases, the HER2 status of the 4 HER2‐positive and 6 HER2‐negative tumors was independently detected by our NGS approach achieving a concordance rate of 100%. The remaining 31 cases were equivocal HER2 cases by IHC of which 5 showed amplification of HER2 by ISH. Our NGS approach classified all non‐amplified cases correctly as HER2 negative and corroborated all but one of the 5 cases with amplified HER2 as detected by ISH. For the overall cohort, concordance between the gold standard and NGS was 97.6% (sensitivity 88.9% and specificity 100%). Additionally, we observed mutations in PIK3CA (44%), HER2 (8%), and CDH1 (6%) among others. Amplifications were found in CCND1 (12%), followed by MYC (10%) and EGFR (2%) and deletions in CDKN2A (10%), MAP2K4 and PIK3R1 (2% each). We here show that targeted NGS data can be used to interrogate the HER2 status with high specificity and high concordance with gold standard methods. Moreover, this approach identifies additional genetic events that may be clinically exploitable. ⓒ 2016 Wiley Periodicals, Inc.


 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기